NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
13 May 2013

Endosense underscores significance of contact force parameters with new study data at heart rhythm 2013

GENEVA – May 13, 2013 – Endosense, a pioneer and leader in contact force (CF) technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, further advanced its leadership position in the field with new study data validating the importance of several proprietary contact force parameters, including its most recently developed Lesion Index (LSI™).
06 May 2013

Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD/17 Million Euros in Series B Financing

BARCELONA - May 6, 2013 - STAT-Diagnostica has announced the closing of a Series B financing round totaling 22.1 million USD/17 million Euros, the proceeds of which will be used to complete development of the company’s Near Patient Testing diagnostic system and clinical validation of its first products.
22 Apr 2013

TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611

Leuven (BELGIUM) – April 22, 2013 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, today announced positive 6-month safety data of its Phase IIa study of Cx611 in rheumatoid arthritis (RA), as well as a first indication of therapeutic activity on standard outcome measures and biologic markers of inflammation for at least three months after dosing.
26 Mar 2013

Endosense’s efficas i study yields new contact force guidelines in catheter ablation treatmentof af: findings published in circulation: arrhythmia and electrophysiology

GENEVA – March 26, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimum contact force (CF), as well as minimum Force Time Integral (FTI™), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF).
12 Mar 2013

TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect®

Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect® will obtain national reimbursement in Spain.
12 Mar 2013

TiGenix Reports Full Year 2012 Financial Results

Leuven (BELGIUM) – March 12, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, today gave a business update and announced financial results for the full year 2012.
05 Mar 2013

Endosense closes an additional USD 4.3 million/CHF 4 million in series C financing

GENEVA – March 5, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner.
01 Feb 2013

First u.s. case performed with endosense’s tacticath quartz contact-force sensing ablation catheter

GENEVA – February 1, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its new generation TactiCath Quartz contact-force sensing ablation catheter has been used for the first time in the United States by Dr. J. Michael Mangrum at University of Virginia Medical Center in Charlottesville, Va.
Inbiomotion appoints Dr. David L. Lacey to its Board of Directors<
29 Jan 2013

Inbiomotion appoints Dr. David L. Lacey to its Board of Directors

Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience.
29 Jan 2013

TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid

Leuven (BELGIUM), Madrid (SPAIN) – January 29, 2013 – TiGenix (Euronext Brussels:TIG), a leader in the field of cell therapy, announced today that further to the cGMPinspection by the Spanish health authorities it has successfully renewed its manufacturingauthorization for stem cell products at its manufacturing facility in Madrid, Spain.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.